A fluorogenic ROS-triggered hydrogen sulfide donor for alleviating cerebral ischemia-reperfusion injury
Theranostics · 04.11.2024 · 14 (19) · 7589-7603
DOI: 10.7150/thno.100930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 04.11.2024. Verfasst von Huangjie Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Burns & Plastic Surgery, Guangzhou Red Cross Hospital, Faculty of Medical Science, Jinan University, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Hydrogen Sulfide, Reactive Oxygen Species, Brain Ischemia. Die Arbeit wurde bisher 31-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Burns & Plastic Surgery, Guangzhou Red Cross Hospital, Faculty of Medical Science, Jinan University, Guangzhou 510006, China.
- College of Pharmacy, Jinan University, Guangzhou 510006, China.
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510006, China.
Zitieren
APA
Lu, H., Zeng, H., Wei, W., Chen, Y., Zhou, Z., Ning, X., & Hu, P. (2024). A fluorogenic ROS-triggered hydrogen sulfide donor for alleviating cerebral ischemia-reperfusion injury. Theranostics, 14(19), 7589-7603. https://doi.org/10.7150/thno.100930
Vancouver
Lu H, Zeng H, Wei W, Chen Y, Zhou Z, Ning X, et al. A fluorogenic ROS-triggered hydrogen sulfide donor for alleviating cerebral ischemia-reperfusion injury. Theranostics. 2024;14(19):7589-7603. doi:10.7150/thno.100930
BibTeX
@article{Lu2024,
author = {Lu, Huangjie and Zeng, Huiying and Wei, Wenlong and Chen, Yuying and Zhou, Ziqiang and Ning, Xuyang and Hu, Ping},
title = {A fluorogenic ROS-triggered hydrogen sulfide donor for alleviating cerebral ischemia-reperfusion injury},
journal = {Theranostics},
year = {2024},
volume = {14},
number = {19},
pages = {7589--7603},
doi = {10.7150/thno.100930}
}
EUVIMED